Notably, EV isolated from MSC of HL patients and HL tumor cell lines treated with the specific ADAM10 inhibitors (Figure 2) retain the ability to inhibit shedding of the ADAM10 substrates MICA, tumor necrosis factor (TNF)α and CD30 in recipient cells [88]. Here, ADAM10 is linked to Hodgkins lymphoma.